AGIO insider trading
NasdaqGS HealthcareAGIOS PHARMACEUTICALS, INC.: insider trade history from SEC Form 4 filings.
About AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Company website: www.agios.com
AGIO insider activity at a glance
FilingIQ tracks 1,099 insider transactions for AGIO in filings since Jan 6, 2015. The most recent transaction is dated Aug 4, 2026.
Across the full history, 7 open-market purchases
and 543 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AGIO insider trades is 57.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AGIO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AGIO?
- FilingIQ tracks 1,099 Form 4 insider transactions for AGIO (AGIOS PHARMACEUTICALS, INC.), covering filings from Jan 6, 2015 onwards. 1 of those are dated within the last 90 days.
- Are AGIO insiders net buyers or net sellers?
- Across the full Form 4 history for AGIO, 7 transactions (1%) were open-market purchases and 543 (49%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AGIO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is AGIO in?
- AGIOS PHARMACEUTICALS, INC. (AGIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.77B.
Methodology & sources
Every AGIO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.